Mar 17, 2022 / 08:30PM GMT
Operator
Good morning. My name is Tom, and I will be your conference operator today. At this time, I would like to welcome everyone to Karyopharm Therapeutics' conference call to discuss its data from SIENDO study. (Operator Instructions)
Be advised that this call is being recorded at the company's request. And I would now like to turn the call over to Elhan Webb, Senior Vice President, Investor Relations. Please go ahead.
Elhan Webb - Karyopharm Therapeutics Inc. - SVP of IR
Thank you, Tom, and thank you all for joining us today to the conference call to discuss our data from the SIENDO study. Today, I'm joined by Richard Paulson, President and CEO; Dr. Patricia Judson, SVP Medical Strategy; and Dr. Robert Coleman from U.S. Oncology Research. In addition, during our Q&A session, we will also be joined by Mike Mason, CFO; and Sohanya Cheng, Chief Commercial Officer.
Detailed results from our Phase III SIENDO study was presented earlier today at the ESMO Virtual Plenaries session. The same data will be presented again at the SGO, Society for
Karyopharm Therapeutics Inc SIENDO Study Results Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot